Jasmohan S. Bajaj, Jacqueline G. O'Leary, K. Rajender Reddy, Florence Wong, Scott W. Biggins, Heather Patton, Michael B. Fallon, Guadalupe Garcia‐Tsao, Benedict Maliakkal, Raza Malik, Ram M. Subramanian, Leroy R. Thacker, Patrick S. Kamath, the North American Consortium for the Study of End-stage Liver Disease (NACSELD) – 20 February 2014 – Infections worsen survival in cirrhosis; however, simple predictors of survival in infection‐related acute‐on‐chronic liver failure (I‐ACLF) derived from multicenter studies are required in order to improve prognostication and resource allocation.

Michael Bauer, Michael Kiehntopf – 20 February 2014

Jesper M. Kivelä, Silja Kosola, Teija Kalajoki‐Helmiö, Heikki Mäkisalo, Hannu Jalanko, Christer Holmberg, Mikko P. Pakarinen, Jouni Lauronen – 18 February 2014 – Hepatic artery thrombosis (HAT) after liver transplantation (LT) increases patient morbidity and mortality. Early HAT is considered to occur within the first month after LT, whereas late HAT occurs after the first month. Few studies have addressed late HAT after LT, especially in pediatric patients. Between 1987 and 2007, 99 patients (age < 18 years) underwent deceased donor LT.

Jayant A. Talwalkar – 15 February 2014 – The Patient Protection and Affordable Care Act (ACA), along with the Health Care and Education Reconciliation Act, was signed into law and upheld by the Supreme Court earlier this year. The ACA contains a variety of reforms that, if implemented, will significantly affect current models of healthcare delivery for patients with acute and chronic hepatobiliary diseases.

Jayant A. Talwalkar – 15 February 2014 – The Patient Protection and Affordable Care Act (ACA), along with the Health Care and Education Reconciliation Act, was signed into law and upheld by the Supreme Court earlier this year. The ACA contains a variety of reforms that, if implemented, will significantly affect current models of healthcare delivery for patients with acute and chronic hepatobiliary diseases.

Ewa Wunsch, Jocelyn Trottier, Malgorzata Milkiewicz, Joanna Raszeja‐Wyszomirska, Gideon M. Hirschfield, Olivier Barbier, Piotr Milkiewicz – 12 February 2014 – Ursodeoxycholic acid (UDCA) is no longer recommended for management of adult patients with primary sclerosing cholangitis (PSC). We undertook a prospective evaluation of UDCA withdrawal in a group of consecutive patients with PSC. Twenty six patients, all treated with UDCA (dose range: 10‐15 mg/kg/day) were included.

Ewa Wunsch, Jocelyn Trottier, Malgorzata Milkiewicz, Joanna Raszeja‐Wyszomirska, Gideon M. Hirschfield, Olivier Barbier, Piotr Milkiewicz – 12 February 2014 – Ursodeoxycholic acid (UDCA) is no longer recommended for management of adult patients with primary sclerosing cholangitis (PSC). We undertook a prospective evaluation of UDCA withdrawal in a group of consecutive patients with PSC. Twenty six patients, all treated with UDCA (dose range: 10‐15 mg/kg/day) were included.

Mickaël Lesurtel, Pierre‐Alain Clavien – 12 February 2014

Ozlem Kucukoglu, Nurdan Guldiken, Yu Chen, Valentyn Usachov, Amin El‐Heliebi, Johannes Haybaeck, Helmut Denk, Christian Trautwein, Pavel Strnad – 12 February 2014 – Mallory‐Denk bodies (MDBs) are protein aggregates consisting of ubiquitinated keratins 8/18 (K8/K18). MDBs are characteristic of alcoholic and nonalcoholic steatohepatitis (NASH) and discriminate between the relatively benign simple steatosis and the more aggressive NASH.

Julien Vergniol, Jérôme Boursier, Clélia Coutzac, Sandrine Bertrais, Juliette Foucher, Camille Angel, Faiza Chermak, Isabelle Fouchard Hubert, Wassil Merrouche, Frédéric Oberti, Victor Lédinghen, Paul Calès – 12 February 2014 – No data are available about the prediction of long‐term survival using repeated noninvasive tests of liver fibrosis in chronic hepatitis C (CHC). We aimed to assess the prognostic value of 3‐year liver stiffness measurement (LSM), aspartate aminotransferase to platelet ratio index (APRI), and fibrosis 4 (FIB‐4) evolution in CHC.